Gilead's GS 504
Company begins a second Phase II/III trial of the nucleotide analog for treatment of cytomegalovirus-associated peripheral retinitis in AIDS patients. The study, being conducted by the 11- center Studies of the Ocular Complications of AIDS (SOCA) research group, will enroll 90 patients. Gilead says it has enrolled half of the 48 patients who will participate in the other pivotal trial, which began in January
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth